Combining additional bulk RNA-sequencing data of these 6 patients with the cohort described by Seki et al. further revealed that patients harboring both the TCF7-SPI1 fusion and NRAS mutations had a higher ETP-ALL signature compared to those with the TCF7-SPI1 fusion alone (Supplementary Fig. 4). This evidence concerns the gene TCF7 and acute lymphoblastic leukemia.